Joshua F Baker1, Philip G Conaghan2, Paul Emery2, Daniel G Baker3, Mikkel Østergaard4. 1. Philadelphia Veterans' Affairs Medical Center, Philadelphia, Pennsylvania, USA University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK. 3. Janssen Research & Development, LLC., Horsham, Pennsylvania, USA. 4. Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: To evaluate the construct validity of the rheumatoid arthritis MRI score (RAMRIS) erosion evaluation as structural damage end point and to assess the potential impact of incorporation in clinical trials. METHODS: In a randomised trial of early methotrexate-naïve RA (GO-BEFORE), RAMRIS scores were determined from MRIs and van der Heijde-Sharp (vdHS) scores from radiographs, at baseline, week 12, week 24 and week 52. Progression in damage scores was defined as change >0.5. Associations of X-ray and MRI outcomes with clinical features were evaluated for convergent validity. Iterative Wilcoxon rank sum tests and tests of proportion estimated the sample size required to detect differences between combination therapy (methotrexate+golimumab) and methotrexate-monotherapy arms in (A) change in damage score and (B) proportion of patients progressing. RESULTS: Patients with early MRI progression had higher DAS28, C reactive protein (CRP) and vdHS at baseline, and higher 2-year HAQ. Associations were similar to those with 1-year vdHS progression. Differences in change in structural damage between treatment arms achieved significance with fewer subjects when 12-week or 24-week MRI erosion score was the outcome (150 patients; 100 among an enriched sample with baseline-synovitis >5) compared with the 52-week vdHS (275 patients). Differences in the proportion progressing could be detected in 234 total subjects with 12-week MRI in an enriched sample whereas 1-year X-ray required between 468 and 1160 subjects. CONCLUSIONS: Early MRI erosion progression is a valid measure of structural damage that could substantially decrease sample size and study duration if used as structural damage end point in RA clinical trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
RCT Entities:
OBJECTIVE: To evaluate the construct validity of the rheumatoid arthritis MRI score (RAMRIS) erosion evaluation as structural damage end point and to assess the potential impact of incorporation in clinical trials. METHODS: In a randomised trial of early methotrexate-naïve RA (GO-BEFORE), RAMRIS scores were determined from MRIs and van der Heijde-Sharp (vdHS) scores from radiographs, at baseline, week 12, week 24 and week 52. Progression in damage scores was defined as change >0.5. Associations of X-ray and MRI outcomes with clinical features were evaluated for convergent validity. Iterative Wilcoxon rank sum tests and tests of proportion estimated the sample size required to detect differences between combination therapy (methotrexate+golimumab) and methotrexate-monotherapy arms in (A) change in damage score and (B) proportion of patients progressing. RESULTS:Patients with early MRI progression had higher DAS28, C reactive protein (CRP) and vdHS at baseline, and higher 2-year HAQ. Associations were similar to those with 1-year vdHS progression. Differences in change in structural damage between treatment arms achieved significance with fewer subjects when 12-week or 24-week MRI erosion score was the outcome (150 patients; 100 among an enriched sample with baseline-synovitis >5) compared with the 52-week vdHS (275 patients). Differences in the proportion progressing could be detected in 234 total subjects with 12-week MRI in an enriched sample whereas 1-year X-ray required between 468 and 1160 subjects. CONCLUSIONS: Early MRI erosion progression is a valid measure of structural damage that could substantially decrease sample size and study duration if used as structural damage end point in RA clinical trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
Anti-TNF; Magnetic Resonance Imaging; Rheumatoid Arthritis
Authors: Mikkel Østergaard; Paul Emery; Philip G Conaghan; Roy Fleischmann; Elizabeth C Hsia; Weichun Xu; Mahboob U Rahman Journal: Arthritis Rheum Date: 2011-12
Authors: Paul Emery; Ferdinand Breedveld; Désirée van der Heijde; Gianfranco Ferraccioli; Maxime Dougados; Deborah Robertson; Ronald Pedersen; Andrew S Koenig; Bruce Freundlich Journal: Arthritis Rheum Date: 2010-03
Authors: Kari Palosaari; Jorma Vuotila; Reijo Takalo; Airi Jartti; Raija K Niemelä; Anna Karjalainen; Marianne Haapea; Irma Soini; Osmo Tervonen; Markku Hakala Journal: Rheumatology (Oxford) Date: 2006-05-02 Impact factor: 7.580
Authors: Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; Zhenhua Xu; John Han; Peter Taylor Journal: Arthritis Rheum Date: 2010-04
Authors: Mikkel Østergaard; Charles Peterfy; Philip Conaghan; Fiona McQueen; Paul Bird; Bo Ejbjerg; Ron Shnier; Philip O'Connor; Mette Klarlund; Paul Emery; Harry Genant; Marissa Lassere; John Edmonds Journal: J Rheumatol Date: 2003-06 Impact factor: 4.666
Authors: Paul Emery; Roy M Fleischmann; Larry W Moreland; Elizabeth C Hsia; Ingrid Strusberg; Patrick Durez; Peter Nash; Eric Jason B Amante; Melvin Churchill; Won Park; Bernardo Antonio Pons-Estel; Mittie K Doyle; Sudha Visvanathan; Weichun Xu; Mahboob U Rahman Journal: Arthritis Rheum Date: 2009-08
Authors: Paul Emery; Roy Fleischmann; Désirée van der Heijde; Edward C Keystone; Mark C Genovese; Philip G Conaghan; Elizabeth C Hsia; Weichun Xu; Anna Baratelle; Anna Beutler; Mahboob U Rahman Journal: Arthritis Rheum Date: 2011-05
Authors: Paul Emery; Désirée van der Heijde; Mikkel Ostergaard; Philip G Conaghan; Mark C Genovese; Edward C Keystone; Roy Fleischmann; Elizabeth C Hsia; Weichun Xu; Stephen Xu; Mahboob U Rahman Journal: Ann Rheum Dis Date: 2011-09-16 Impact factor: 19.103
Authors: Xenofon Baraliakos; Philip G Conaghan; Maria-Antonietta D'Agostino; Walter Maksymowych; Esperanza Naredo; Mikkel Ostergaard; Georg Schett; Paul Emery Journal: Eur J Rheumatol Date: 2019-01
Authors: Christoph Treutlein; Tobias Bäuerle; Armin M Nagel; Ali Guermazi; Arnd Kleyer; David Simon; Georg Schett; Tobias Hepp; Michael Uder; Frank W Roemer Journal: BMC Musculoskelet Disord Date: 2020-02-21 Impact factor: 2.362